Clinical anti-myeloma drugs were shown to induce syndecan-1 shedding in multiple myeloma cell cultures and in tumor xenografted mice, as well as the upregulation of heparanase expression and its release into conditioned medium. This evidence concerns the gene SDC1 and plasma cell myeloma.